中国非小细胞肺癌免疫检查点抑制剂治疗专家共识(2020年版)

Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer(2020 Version)

非小细胞肺癌(non-small cell lung cancer,NSCLC)是肺癌最常见的病理类型。晚期NSCLC的系统性抗肿瘤治疗经历了化疗、靶向治疗及免疫治疗的变革,患者总体生存时间不断延长。免疫检查点抑制剂(immune checkpoint inhibitors,ICIs),尤其是程序性死亡分子-1(programmed cell death protein 1,PD-1)/程序性死亡分子配体-1(programmed death-ligand 1,PD-L1)抗体已成为表皮生长因子受体(epidermal growth factor receptor,EGFR)/间变性淋巴瘤激酶(anaplastic lymphoma kinase,ALK)阴性晚期NSCLC一线及二线的标准治疗和局部晚期NSCLC同步放化疗后标准治疗,并在辅助/新辅助治疗中显示出可喜的结果,改变了NSCLC整体治疗格局。随着越来越多的ICIs在国内获批肺癌适应证,中国临床肿瘤学会(Chinese Society of Clinical Oncology,CSCO)NSCLC专家委员会牵头,组织该领域的专家,结合2019年版专家共识,参考最新国内外文献、临床研究数据及系统评价,在专家共同讨论的基础上,达成统一意见并制定、更新本共识,为国内同行更好地应用ICIs治疗NSCLC提供参考意见。

Non-small cell lung cancer(NSCLC)is the most common pathological type of lung cancer.The systemic antitumor therapy of advanced NSCLC has undergone renovations of chemotherapy,targeted therapy and immunotherapy,which results in greatly improved survival for patients with advanced NSCLC.Immune checkpoint inhibitors(ICIs),especially targeting programmed cell death protein 1(PD-1)/programmed death-ligand 1(PD-L1),has changed the treatment paradigm of NSCLC.ICIs have become the standard treatment for advanced NSCLC without epidermal growth factor receptor(EGFR)mutation or anaplastic lymphomakinase(ALK)translocation in the first-or second-line setting,and for locally advanced NSCLC following concurrent radiotherapy and chemotherapy.ICIs are also promising in adjuvant/neoadjuvant therapy.More and more ICIs have been approved domestically for the treatment of NSCLC.Led by the NSCLC expert committee of Chinese Society of Clinical Oncology(CSCO),this consensus was developed and updated based on thoroughly reviewing domestic and foreign literatures,clinical trial data,systematic reviews,experts’discussion and the consensus(2019 version).This consensus will aid domestic clinicians in the treatment of NSCLC with ICIs.